Table 2. Toxicities in Patients Treated With Pembrolizumab Treatment.
| Any grade | Grade 3 | |
|---|---|---|
| Treatment-related AEs, n (%) | 21 (62) | 8 (24) |
| Fatigue | 6 | 2 |
| Pruritus | 5 | 0 |
| Fever | 2 | 0 |
| Hematuria | 2 | 2 |
| Anorexia | 2 | 1 |
| Lung infection | 2 | 1 |
| Pain | 1 | 1 |
| Anemia | 1 | 1 |
| Kidney infection | 1 | 1 |
| Creatinine increased | 1 | 1 |
| Aspartate and alanine aminotransferase increased | 1 | 1 |
| Constipation | 1 | 0 |
| Infusion related reaction | 1 | 0 |
| Diarrhea | 1 | 0 |
| Ileus | 1 | 0 |
| Interstitial pneumonia | 1 | 0 |
| Hyponatremia | 1 | 0 |
| Eyelid function disorder | 1 | 0 |
| Nervous system disorders | 1 | 0 |
AEs: adverse events.